



Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are studying the use of an immunotherapy medication called Pembrolizumab, with two other chemotherapy medications, Capecitabine and Oxaliplatin. Oxaliplatin and Capecitabine are widely used to treat different types of gastrointestinal cancers. The researchers want to see if when these medications are used together, they will support the immune system to better fight cancer cells. Pembrolizumab targets PD-1, a protein found on T cells that helps control your body's immune system response. When PD-1 attaches to PD-L1 (a protein found on some cancer cells), it can stop T cells from killing the cancer cells. Therapies like Pembrolizumab can make it harder for cancer cells to hide from T cells, so that the immune system can find them and try to attack them. We hope this combination when given together, may result in a new a way of treating patients with biliary tract carcinoma (BTC).

CONTACT
THE NIH CLINICAL CENTER
Office of Patient Recruitment

Study #17-C-0082

800-411-1222

prpl@cc.nih.gov

<https://go.usa.gov/xpKfg>

TTY for Deaf, Hard-of-Hearing, or Speech
Impaired

800-877-8339 TTY/ASCII

All study-related treatments, tests, and
care provided at no cost.



**NATIONAL
CANCER
INSTITUTE**

NIH Clinical Center, America's Research Hospital,
located in Bethesda, MD
on the Metro Redline (Medical Center stop)